HLB Innovation subsidiary Verismo Therapeutics has licensed Stanford’s PACK-IT technology to develop in vivo CAR-T therapies, aiming to reduce manufacturing costs.
HLB Innovation’s Verismo Therapeutics Secures Stanford’s In Vivo CAR-T Technology
HLB Innovation subsidiary Verismo Therapeutics has licensed Stanford’s PACK-IT technology to develop in vivo CAR-T therapies, aiming to reduce manufacturing costs.

MTIMES Global Editorial Statement
This analysis is provided for international business intelligence and informational purposes only. It does not constitute investment advice or a solicitation to buy or sell securities. For inquiries regarding licensing or syndication, please contact [email protected].






